Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY1R | P25929 | 3/20 | 0.39 |
| ▸ | CRHR1 | P34998 | 12/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5826859 | 0.99 | NPY1R (0.38) | NPY1RCRHR1KDM4ENPC1ALDH1A1 | |
| SCHEMBL5827024 | 0.92 | CRHR1 (0.41) | NPY1RCRHR1KDM4ENPC1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL5826965 | 0.91 | CRHR1 (0.40) | NPY1RCRHR1KDM4ENPC1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL5827185 | 0.88 | MAPT (0.37) | CRHR1KDM4ENPC1ALDH1A1RAB9A | |
| SCHEMBL5826900 | 0.87 | CRHR1 (0.39) | NPY1RCRHR1KDM4ENPC1ALDH1A1 | |
| SCHEMBL5826809 | 0.87 | CRHR1 (0.42) | NPY1RCRHR1KDM4EALDH1A1MAPT | |
| SCHEMBL5826876 | 0.86 | CRHR1 (0.42) | NPY1RCRHR1KDM4ENPC1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL5827223 | 0.85 | CRHR1 (0.42) | NPY1RCRHR1KDM4ENPC1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL5826489 | 0.84 | KDM4E (0.44) | NPY1RCRHR1KDM4ENPC1ALDH1A1 | |
| SCHEMBL6211073 | 0.84 | KDM4E (0.35) | NPY1RCRHR1KDM4ENPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030078277-A1 | Fused heterotricyclic compounds, process for preparing the compounds and drugs containing the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2003-04-24 | — | — | US | claimed |
| EP-1238979-A1 | FUSED HETEROTRICYCLIC COMPOUNDS, PROCESS FOR PREPARING THE COMPOUNDS AND DRUGS CONTAINING THE SAME | Eisai Co., Ltd. (JP) | 2002-09-11 | — | — | EP | claimed |
| US-6995163-B2 | Tricyclic fused heterocyclic compound, process for preparing it and medicament comprising it | EISAI CO., LTD. (JP) | 2006-02-07 | — | — | US | disclosed |
| US-6951865-B2 | Fused heterotricyclic compounds, process for preparing the compounds and drugs containing the same | EISAI CO., LTD. (JP) | 2005-10-04 | — | — | US | disclosed |
| US-6927221-B2 | Tricyclic fused heterocyclic compound, process for preparing it and medicament comprising it | EISAI CO., LTD. (JP) | 2005-08-09 | — | — | US | disclosed |
| EP-1238979-B1 | FUSED HETEROTRICYCLIC COMPOUNDS, PROCESS FOR PREPARING THE COMPOUNDS AND DRUGS CONTAINING THE SAME | EISAI CO LTD (JP) | 2005-03-02 | — | — | EP | disclosed |
| US-20050004159-A1 | Tricyclic fused heterocyclic compound, process for preparing it and medicament comprising it | EISAI CO., LTD. | 2005-01-06 | — | — | US | disclosed |
| US-20050004147-A1 | Tricyclic fused heterocyclic compound, process for preparing it and medicament comprising it | EISAI CO., LTD. | 2005-01-06 | — | — | US | disclosed |
| EP-1408040-A1 | Tricyclic fused heterocyclic compounds as CRFantagonists | Eisai Co., Ltd. (JP) | 2004-04-14 | — | — | EP | disclosed |
| US-20030078277-A1 | Fused heterotricyclic compounds, process for preparing the compounds and drugs containing the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2003-04-24 | — | — | US | disclosed |
| EP-1238979-A1 | FUSED HETEROTRICYCLIC COMPOUNDS, PROCESS FOR PREPARING THE COMPOUNDS AND DRUGS CONTAINING THE SAME | Eisai Co., Ltd. (JP) | 2002-09-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078277-A1 | Fused heterotricyclic compounds, process for preparing the compounds and drugs containing the same | NR3C2, CRHR1, CRHR2 | NPY1R 101/4885CRHR1 2/4885KDM4E 3439/4885 |
| US-20050004159-A1 | Tricyclic fused heterocyclic compound, process for preparing it and medicament comprising it | CRHR2, CRHR1, NR3C2 | NPY1R 130/4885CRHR1 2/4885KDM4E 4135/4885 |
| US-20050004147-A1 | Tricyclic fused heterocyclic compound, process for preparing it and medicament comprising it | CRHR2, CRHR1, NR3C2 | NPY1R 130/4885CRHR1 2/4885KDM4E 4135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.